United Kingdom

People: Aytu BioScience Inc (AYTU.OQ)

AYTU.OQ on NASDAQ Stock Exchange Capital Market

23 Aug 2019
Change (% chg)

$-0.05 (-3.26%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Disbrow, Joshua 

Mr. Joshua R. (Josh) Disbrow is Chairman, Chief Executive Officer, Director of the Company. Joshua R. Disbrow has been employed by us since April 16, 2015 and a member of our Board of Directors since January 2016. Prior to the closing of the merger with Luoxis Diagnostics, Inc. and Vyrix Pharmaceuticals, Inc. that formed Aytu BioScience, Mr. Disbrow was the Chief Executive Officer of Luoxis since January 2013. Mr. Disbrow served as the Chief Operating Officer of Ampio Pharmaceuticals, Inc. (“Ampio”) from December 2012 until April 2015. Prior to joining Ampio, he served as the Vice President of Commercial Operations at Arbor Pharmaceuticals LLC (“Arbor”), a specialty pharmaceutical company, from May 2007 through October 2012. He joined Arbor as that company’s second full-time employee. Mr. Disbrow led the company’s commercial efforts from inception to the company’s acquisition in 2010 and growth to over $127 million in net sales in 2011. By the time Mr. Disbrow departed Arbor in late 2012, he handled the growth of the commercial organization to comprise over 150 people in sales, marketing sales training, managed care, national accounts, and other commercial functions. Mr. Disbrow has spent over 17 years in the pharmaceutical, diagnostic and medical device industries and has held positions of increasing responsibility in sales, marketing, sales management, commercial operations and commercial strategy. Prior to joining Arbor, Mr. Disbrow served as Regional Sales Manager with Cyberonics, Inc., a medical device company focused on neuromodulation therapies from June 2005 through April 2007. Prior to joining Cyberonics he was the Director of Marketing at LipoScience Inc., an in vitro diagnostics company. Mr. Disbrow holds an MBA from Wake Forest University and BS in Management from North Carolina State University.

Basic Compensation

Total Annual Compensation, USD 250,000
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 803,000
Fiscal Year Total, USD 1,053,000

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --